New drug CM082 and JS001 jointclinical clinical trial application spree for melanoma has been accepted by the National Drug Administration

recently,, Beida Pharmaceuticals announced that theof the wholly-owned sub-
company (KananjiPharmaceutical(Shanghai) Co., Ltdreceived the NationalPharmaceutical(The Notice of Acceptance of drug registration applications issued by the Supervisory Authority), KananjiNew Drug(CM082) and Shanghai Junshi Biopharmaceutical Technology Co., Ltdnew
drug Tripri (JS001) to be jointly used in the previous untreated local or transferof melanomaabout CM082
CM082 is a multi-target receptor tyrosine kinase (RTKs) inhibitor for VEGFR and PDGFR targets, which can inhibit neo-angiogenesis and tumor growth, and is a new drug with a new generation of target-specific anti-tumor small molecules, registered as a chemical class 1.1CM082 not only has obvious efficacy for VEGFR and PDGFR targets, but also overcomes the high toxic side effects commonly associated with this type of targeted drug, and ongoing clinical studies include Phase III clinical trials of CM082 and Evemos in conjunction with the treatment of renal transparent cell carcinoma, as well as Phase I clinical trials for age-related macular degenerationannouncement shows that Beida Pharmaceuticals, through its subsidiary Kananji, has a Chinese interest in CM082's all-indications Up to now, the company for the drug (has invested in research and development costs of about 38.3538 million yuan about JS001
JS001 is a new recombinant humanized anti-PD-1 monoclonal antibody developed by Junshi Bio Junshi Bio submitted its listing application on March 8, 2018 for local progression or metastatic melanoma after the failure of previous standard treatments, registered as a therapeutic biological product category 1 the clinical trial for treatment of previously untreated local progression or metastatic mucosal melanoma is an exploration of a combination of antiangiogenic therapy and immunotherapy to treat mucosa melanoma Junshi Bio has done a comprehensive and systematic study of the clinical trial, submitted a clinical trial application and received the formal acceptance